2016 Article Archive
A UT Southwestern Medical Center study comparing two types of materials used in abdominal wall hernia repair surgery found no evidence to support the use of costlier biologic mesh versus synthetic mesh.
HPV vaccination is our best defense in stopping HPV infection in our youth and preventing HPV-related cancers in our communities.
The 1 Million 4 Anna Foundation has awarded its largest grant thus far to UT Southwestern Medical Center’s research project targeting Ewing's sarcoma, a malignant bone cancer that affects primarily adolescents and young adults.
UT Southwestern Medical Center researchers have deciphered how a small protein made by the human immunodeficiency virus (HIV) that causes AIDS manipulates human genes to further its deadly agenda.
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
HPREP is the Medical Center’s “academically challenging enrichment program that offers minority and underrepresented high-school students a glimpse of education and career opportunities in health care professions.
Dr. Marc Nivet lives one mile from the invisible line that divides Washington, D.C., from Arlington, Virginia, but that short distance makes a world of difference in educational quality for his 11-year-old son.
Michael Braitsch, a student the Doctor of Physical Therapy program, has received the 2016 Martin Luther King Jr. Scholarship for Community Service Award in recognition of his many volunteering endeavors.
Tumor-suppressing gene works by restraining mobile genetic elements that can lead to genomic instability
The most commonly mutated gene in cancer, p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Study identifies how certain drugs alter the metabolism of pancreatic cancer cells, revealing a new therapeutic target
UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain.